526 Pharmacokinetic and pharmacodynamic analyses of PD-1 blockade with nivolumab at varying doses and schedules supports administration at markedly reduced dose and frequency

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Medicine

Cancer Oncology

Internal Medicine

Psychiatry And Mental Health

Nivolumab

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0526

License

CC-BY-NC

Other Formats

PDF